DBV Technologies (NASDAQ:DBVT) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report released on Thursday morning. The brokerage issued a hold rating on the stock.

Other analysts have also recently issued reports about the stock. JMP Securities upped their price objective on shares of DBV Technologies from $4.00 to $5.00 and gave the stock a market outperform rating in a research note on Wednesday, July 31st. HC Wainwright restated a buy rating and set a $5.00 price target on shares of DBV Technologies in a research report on Thursday, August 1st.

DBV Technologies Price Performance

DBV Technologies stock opened at $0.75 on Thursday. The business has a 50 day simple moving average of $0.87 and a 200 day simple moving average of $1.10. The company has a market capitalization of $71.89 million, a PE ratio of -0.89 and a beta of 0.68. DBV Technologies has a one year low of $0.50 and a one year high of $2.92.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. The company had revenue of $1.16 million for the quarter, compared to the consensus estimate of $1.42 million. During the same period in the previous year, the business posted ($0.26) earnings per share. Equities analysts anticipate that DBV Technologies will post -1.43 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. lifted its stake in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the period. DBV Technologies accounts for 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th largest position. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 71.74% of the stock is currently owned by institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.